Literature DB >> 6271798

Determination of ranitidine and its metabolites in human urine by reversed-phase ion-pair high-performance liquid chromatography.

P F Carey, L E Martin, P E Owen.   

Abstract

A method using ion-pair high-performance liquid chromatography is presented for determining ranitidine, ranitidine N-oxide, ranitidine S-oxide and desmethyl ranitidine in the urine from four volunteers, given on separate occasions an intravenous and oral dose of 100 mg ranitidine. This method has been used to study the metabolism and pharmacokinetics of ranitidine by man. It was found that the elimination half-life of ranitidine ranged from 110-246 min. The mean renal clearance of ranitidine in these four volunteers was 512 ml/min.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6271798     DOI： 10.1016/s0378-4347(00)80255-8

Source DB:  PubMed          Journal:  J Chromatogr


  11 in total

Review 1.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

2.  Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid.

Authors:  K M Deppermann; H Lode; G Höffken; G Tschink; C Kalz; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

3.  Daytime acid secretion after a single dose of ranitidine and cimetidine--a double blind crossover study.

Authors:  V F Eckardt; I Cordes; H D Janisch; H Wiemann
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Ranitidine: single dose pharmacokinetics and absolute bioavailability in man.

Authors:  A M van Hecken; T B Tjandramaga; A Mullie; R Verbesselt; P J de Schepper
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

Review 5.  Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  R N Brogden; A A Carmine; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

Review 6.  Clinical pharmacokinetics of ranitidine.

Authors:  C J Roberts
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

Review 7.  Interactions and non-interactions with ranitidine.

Authors:  W Kirch; H Hoensch; H D Janisch
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

8.  Plasma ranitidine concentrations after intravenous administration in normal volunteers and haemodialysis patients.

Authors:  A P Roberts; C Harrison; G T Dixon; J R Curtis
Journal:  Postgrad Med J       Date:  1983-01       Impact factor: 2.401

9.  Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females.

Authors:  Diane A I Ashiru; Rajesh Patel; Abdul W Basit
Journal:  Pharm Res       Date:  2008-07-04       Impact factor: 4.200

Review 10.  Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models.

Authors:  Xiaomin Deng; James P Luyendyk; Patricia E Ganey; Robert A Roth
Journal:  Pharmacol Rev       Date:  2009-09       Impact factor: 25.468
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.